274 related articles for article (PubMed ID: 33046443)
1. Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma.
Rusert JM; Juarez EF; Brabetz S; Jensen J; Garancher A; Chau LQ; Tacheva-Grigorova SK; Wahab S; Udaka YT; Finlay D; Seker-Cin H; Reardon B; Gröbner S; Serrano J; Ecker J; Qi L; Kogiso M; Du Y; Baxter PA; Henderson JJ; Berens ME; Vuori K; Milde T; Cho YJ; Li XN; Olson JM; Reyes I; Snuderl M; Wong TC; Dimmock DP; Nahas SA; Malicki D; Crawford JR; Levy ML; Van Allen EM; Pfister SM; Tamayo P; Kool M; Mesirov JP; Wechsler-Reya RJ
Cancer Res; 2020 Dec; 80(23):5393-5407. PubMed ID: 33046443
[TBL] [Abstract][Full Text] [Related]
2. Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma.
Genovesi LA; Millar A; Tolson E; Singleton M; Hassall E; Kojic M; Brighi C; Girard E; Andradas C; Kuchibhotla M; Bhuva DD; Endersby R; Gottardo NG; Bernard A; Adolphe C; Olson JM; Taylor MD; Davis MJ; Wainwright BJ
Genome Med; 2021 Jun; 13(1):103. PubMed ID: 34154646
[TBL] [Abstract][Full Text] [Related]
3. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
Singh AR; Joshi S; Zulcic M; Alcaraz M; Garlich JR; Morales GA; Cho YJ; Bao L; Levy ML; Newbury R; Malicki D; Messer K; Crawford J; Durden DL
PLoS One; 2016; 11(3):e0150836. PubMed ID: 26938241
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.
Diaz RJ; Golbourn B; Faria C; Picard D; Shih D; Raynaud D; Leadly M; MacKenzie D; Bryant M; Bebenek M; Smith CA; Taylor MD; Huang A; Rutka JT
Oncotarget; 2015 Feb; 6(5):3359-74. PubMed ID: 25739120
[TBL] [Abstract][Full Text] [Related]
5. Next-Generation Profiling of Medulloblastoma: Old Drugs Are an Elegant Weapon in a Civilized Age.
Nör C; Ramaswamy V
Cancer Res; 2021 Jan; 81(2):264-265. PubMed ID: 33452214
[TBL] [Abstract][Full Text] [Related]
6. DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets.
Hanaford AR; Archer TC; Price A; Kahlert UD; Maciaczyk J; Nikkhah G; Kim JW; Ehrenberger T; Clemons PA; Dančík V; Seashore-Ludlow B; Viswanathan V; Stewart ML; Rees MG; Shamji A; Schreiber S; Fraenkel E; Pomeroy SL; Mesirov JP; Tamayo P; Eberhart CG; Raabe EH
Clin Cancer Res; 2016 Aug; 22(15):3903-14. PubMed ID: 27012813
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of miR-204 expression defines a highly aggressive subset of Group 3/Group 4 medulloblastomas.
Bharambe HS; Paul R; Panwalkar P; Jalali R; Sridhar E; Gupta T; Moiyadi A; Shetty P; Kazi S; Deogharkar A; Masurkar S; Yogi K; Kunder R; Gadewal N; Goel A; Goel N; Chinnaswamy G; Ramaswamy V; Shirsat NV
Acta Neuropathol Commun; 2019 Apr; 7(1):52. PubMed ID: 30944042
[TBL] [Abstract][Full Text] [Related]
8. Medulloblastoma: Molecular understanding, treatment evolution, and new developments.
Liu X; Ding C; Tan W; Zhang A
Pharmacol Ther; 2020 Jun; 210():107516. PubMed ID: 32105673
[TBL] [Abstract][Full Text] [Related]
9. Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo.
Lee SJ; Krauthauser C; Maduskuie V; Fawcett PT; Olson JM; Rajasekaran SA
BMC Cancer; 2011 Apr; 11():144. PubMed ID: 21501498
[TBL] [Abstract][Full Text] [Related]
10. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations.
Thompson MC; Fuller C; Hogg TL; Dalton J; Finkelstein D; Lau CC; Chintagumpala M; Adesina A; Ashley DM; Kellie SJ; Taylor MD; Curran T; Gajjar A; Gilbertson RJ
J Clin Oncol; 2006 Apr; 24(12):1924-31. PubMed ID: 16567768
[TBL] [Abstract][Full Text] [Related]
11. Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma.
Brun SN; Markant SL; Esparza LA; Garcia G; Terry D; Huang JM; Pavlyukov MS; Li XN; Grant GA; Crawford JR; Levy ML; Conway EM; Smith LH; Nakano I; Berezov A; Greene MI; Wang Q; Wechsler-Reya RJ
Oncogene; 2015 Jul; 34(29):3770-9. PubMed ID: 25241898
[TBL] [Abstract][Full Text] [Related]
12. Signaling pathway and molecular subgroups of medulloblastoma.
Li KK; Lau KM; Ng HK
Int J Clin Exp Pathol; 2013; 6(7):1211-22. PubMed ID: 23826403
[TBL] [Abstract][Full Text] [Related]
13. A chemical screen for medulloblastoma identifies quercetin as a putative radiosensitizer.
Lagerweij T; Hiddingh L; Biesmans D; Crommentuijn MH; Cloos J; Li XN; Kogiso M; Tannous BA; Vandertop WP; Noske DP; Kaspers GJ; Würdinger T; Hulleman E
Oncotarget; 2016 Jun; 7(24):35776-35788. PubMed ID: 26967057
[TBL] [Abstract][Full Text] [Related]
14. Inter and intra-tumoral heterogeneity as a platform for personalized therapies in medulloblastoma.
Danilenko M; Clifford SC; Schwalbe EC
Pharmacol Ther; 2021 Dec; 228():107828. PubMed ID: 33662447
[TBL] [Abstract][Full Text] [Related]
15. Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity.
Vassal G; Boland I; Terrier-Lacombe MJ; Watson AJ; Margison GP; Vénuat AM; Morizet J; Parker F; Lacroix C; Lellouch-Tubiana A; Pierre-Kahn A; Poullain MG; Gouyette A
Clin Cancer Res; 1998 Feb; 4(2):463-8. PubMed ID: 9516937
[TBL] [Abstract][Full Text] [Related]
16. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma.
Purzner T; Purzner J; Buckstaff T; Cozza G; Gholamin S; Rusert JM; Hartl TA; Sanders J; Conley N; Ge X; Langan M; Ramaswamy V; Ellis L; Litzenburger U; Bolin S; Theruvath J; Nitta R; Qi L; Li XN; Li G; Taylor MD; Wechsler-Reya RJ; Pinna LA; Cho YJ; Fuller MT; Elias JE; Scott MP
Sci Signal; 2018 Sep; 11(547):. PubMed ID: 30206138
[TBL] [Abstract][Full Text] [Related]
17. Notch1 regulates the initiation of metastasis and self-renewal of Group 3 medulloblastoma.
Kahn SA; Wang X; Nitta RT; Gholamin S; Theruvath J; Hutter G; Azad TD; Wadi L; Bolin S; Ramaswamy V; Esparza R; Liu KW; Edwards M; Swartling FJ; Sahoo D; Li G; Wechsler-Reya RJ; Reimand J; Cho YJ; Taylor MD; Weissman IL; Mitra SS; Cheshier SH
Nat Commun; 2018 Oct; 9(1):4121. PubMed ID: 30297829
[TBL] [Abstract][Full Text] [Related]
18. UAB30, a novel RXR agonist, decreases tumorigenesis and leptomeningeal disease in group 3 medulloblastoma patient-derived xenografts.
Garner EF; Stafman LL; Williams AP; Aye JM; Goolsby C; Atigadda VR; Moore BP; Nan L; Stewart JE; Hjelmeland AB; Friedman GK; Beierle EA
J Neurooncol; 2018 Nov; 140(2):209-224. PubMed ID: 30132166
[TBL] [Abstract][Full Text] [Related]
19. Systems biology-based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma.
Huang L; Garrett Injac S; Cui K; Braun F; Lin Q; Du Y; Zhang H; Kogiso M; Lindsay H; Zhao S; Baxter P; Adekunle A; Man TK; Zhao H; Li XN; Lau CC; Wong STC
Sci Transl Med; 2018 Oct; 10(464):. PubMed ID: 30355798
[TBL] [Abstract][Full Text] [Related]
20. A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma.
Chaturvedi NK; Kling MJ; Griggs CN; Kesherwani V; Shukla M; McIntyre EM; Ray S; Liu Y; McGuire TR; Sharp JG; Band H; Joshi SS; Coulter DW
Mol Cancer Ther; 2020 Jun; 19(6):1351-1362. PubMed ID: 32371591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
